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Abstract Obesity is associated with blunted growth
hormone (GH) secretion. In some individuals, hypotha-
lamic–pituitary (HP) structural lesions may contribute to
GH deficiency (GHD). We explored pituitary morphology
in obese patients with suspected GHD and its association
with cardiovascular risk factors, body composition, and
cardiac morphology. One hundred and eighty-four adults
obese patients with symptoms and signs of GHD (147
females and 37 males; mean age 46.31 ± 12.11 years), out
of 906 consecutive white obese outpatients, were evalu-
ated. The main measures were anthropometric data, blood
pressure, lipid profile, glycemic parameters, pituitary hor-
mones, and insulin-like growth factor-1 values, echocar-
diography, magnetic resonance imaging (MRI) of the HP
region, body composition, and growth hormone-releasing
hormone plus arginine test. Seventy patients had GHD (GH
peak values \4.2 lg/mL). GHD patients showed signifi-
cantly higher body mass index and fat mass, lower lumbar
bone mineral density, increased left ventricular mass index,
and epicardial fat thickness. The MRI of the HP region
showed empty sella (ES) in 69 and normal pituitary in one
of the 70 GHD patients; the 114 patients with normal GH
response had ES (n = 62, 54 %), normal pituitary (n = 37,
32 %), microadenomas (n = 10, 8 %), and other pituitary
abnormalities (n = 5, 4 %). ES was a significant inde-
pendent predictor of GH secretory capacity as determined
by multiple regression analysis. The close relationship
between ES and GH secretory capacity points out to the
possibility of the organic nature of GHD in a portion of
obese individuals and opens a new scenario with regard to
the potential of GH treatment on metabolic consequences
of obesity.
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Introduction
Obesity is a disease not always attributable to caloric
imbalance, and various hypotheses are emerging to
explain, at least in part, this growing epidemic [1]. The
identification of conditions with causative roles in the
development and maintenance of obesity and its comor-
bidities may have important clinical consequences.
Neuroendocrine dysfunctions are frequent in obese
patients, and the common assumption is that they are func-
tionally linked to increased adipose tissue with potential for
delayed identification and investigation of HP diseases [2].
The HP unit plays a central role in the maintenance of
normal weight being directly involved in the control of
energy homeostasis [3]. Either insufficiency or excess of
anterior pituitary hormones have subtle effects on the
accumulation of body fat severity of which depends on the
mixture of changes, their degree, and duration. For exam-
ple, Cushing’s disease and excess of prolactin (PRL) may
be associated with increased visceral fat; insufficiencies of
anterior pituitary hormones affect the accumulation of
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adipose tissue [2]. A blunted growth hormone (GH)
response is a frequent feature in obese individuals gener-
ally considered a functional result of obesity. However,
obesity associates with profound changes in the structure of
neurons and glia in the hypothalamus [4] and frequently
shares with ES, idiopathic intracranial hypertension, and
high intracranial pressure, all conditions with some degree
of hypopituitarism [5, 6]. Collectively, abnormalities of the
HP unit may be either a consequence of obesity or con-
tribute to its development through a persistent organic
failure. Therefore, in the obese patients with clinical
characteristics of HP disease, an adequate functional and
morphological assessment of HP unit is important to
improve health outcomes [7].
We evaluated HP MRI findings and cardiometabolic
condition in obese individuals with clinical features of
GHD. We report evidence that among the obese individ-
uals, the coexistence of signs and symptoms of GHD other
than obesity is frequent, and there is a marked association
of ES with severe GHD. Furthermore, we found a signifi-
cant relationship between the impaired GH secretion and
the metabolic unhealthy phenotype in obese patients.
Materials and methods
Study design and participants
Nine hundred and six consecutive unselected white obese
outpatients [676 females and 230 males; age range
11–64 years, mean ± SD 42.36 ± 13.09 years; BMI,
expressed as weight (kg)/height (m2) C30 kg/m2], referred
to our center for a first-level approach to the study of
obesity and its comorbidities, were evaluated for a clinical,
metabolic, and therapeutic assessment of obesity during the
period of 2007–2013. All patients underwent neurological,
ophthalmological, and baseline endocrine evaluations.
184 patients (37 males, 147 females, mean age 46.31 ±
12.11 years) with normal GH values and normal-to-low
levels of IGF-1 for sex and age, in an appropriate clinical
context [8], namely those with signs and symptoms of
GHD according to the Endocrine Society consensus
guidelines [9], underwent the GHRH plus arginine test
(Fig. 1). In particular, patients were selected if presenting
IGF1 standard deviation score (SDS) between -1 and -3
and at least one symptom and one sign among these:
lumbar T score \ -1; lean mass% \ 60 %; upper body fat
deposition index (UFDI), the ratio between upper body fat
(neck, arms, and trunk fat in kg) and lower body fat (legs
fat in kg) [1.5; epicardial fat thickness (EFT) [7 mm in
females and [8 mm in males; ejection fraction
(EF) \ 60 %; diastolic left ventricular diameter
(DLVD) [ 55 mm; systolic left ventricular diameter
(SLVD) [ 43 mm; LVMI [ 100 g/m2; altered triglycer-
ides ([1.69 mmol/L), or total cholesterol ([5.17 mmol/L)
levels. Exclusion criteria were short stature or decreased
growth rate issues in childhood, pregnancy, lactation, or
drugs known to affect pituitary function.
If adrenocorticotropic hormone (ACTH) deficiency was
suspected, insulin tolerance test and cortisol daily curves
were performed [9].
No patient was treated with any drug until first line
evaluation and stimulation tests were performed.
The study was approved by the biomedical research
ethic committee of the University of Rome ‘‘La Sapienza.’’
This study is registered with ClinicalTrials.gov, number
NCT02092779. All patients provided a written informed
consent according to the Declaration of Helsinki.
Clinical measurements
Weight and height were measured to the nearest 0.1 kg and
0.1 cm, respectively. The waist circumference (WC) was
measured just above the bony landmark of the iliac crest
and expressed in centimeters. Hip circumference was
measured around the pelvis at the point of maximal pro-
trusion of the buttocks. Sitting systolic and diastolic blood
pressure (SBP–DBP) was measured twice at 5-min inter-
vals, and the average of two measurements was used for
analysis.
Laboratory
Blood samples were collected after an overnight fast. Lipid
status [total cholesterol (total-C), HDL cholesterol (HDL-
C), and triglycerides (TG)] were determined using auto-
mated enzymatic method (Dade Behring SPA Milan). LDL
cholesterol (LDL-C) was calculated using the Friedwald
formula. The glucose determinations were performed using
the hexokinase method (Aeroset Abbot Park, IL, USA),
insulin was measured by radioimmuno-assay (Bayer
906 obese outpatients
184 with signs and symptoms
of GHD* submitted to GHRH +
arginine test
70 GHD** 114 normal response toGHRH + arginine test 
Fig. 1 Study design. GHD growth hormone deficiency; * according
to (8, 9), ** peak value to GHRH plus arginine test \4.2 lg/L
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Diagnostics, Milan, Italy). Homeostasis model assessment
of insulin resistance (HOMA-IR) was calculated from
Matthews et al. [10]. HbA1c was determined by an auto-
mated system (Bio-Rad Laboratories, Hercules, CA, USA).
IGF-1 was assayed by an immunoradiometric assay
(Diagnostic System Laboratories Inc., Webster, TX, USA).
Thyroid-stimulating hormone (TSH) and PRL measure-
ments were performed by chemiluminescence (Abbott
Laboratories, Abbott Park, IL, USA). ACTH and GH were
measured by radioimmuno-assay (CISbio, Cedex, France;
DiaSorin S.p.A., VC, Italy). All samples were assayed in
duplicate, with intra-assay and inter-assay mean coeffi-
cients of variation of 2 and 4 %, respectively. The GHRH
plus arginine test was performed as follows. One micro-
gram per kilogram of body weight of intravenous GHRH
(Ghrh Ferring, Ferring S.p.A., Milano, Italy) as a bolus plus
0.5 g/kg of body weight up to a maximum of 30 g of
arginine hydrochloride (iv infusion over 30 min) were
given, and blood samples were taken at -15, 0, and ?30,
?45, ?60 after stimulation. GH results were read with
BMI-dependent cut-off values for diagnosis of adult GHD,
as suggested by Corneli et al., in respect of a reference
obese Italian population with multiple pituitary hormone
deficits [11]: peak value\4.2 lg/L for obese patients. The
area under the concentration–time curve (AUC) was cal-
culated by the trapezoidal method.
Magnetic resonance imaging (MRI)
Pituitary gland MRI was performed using a 1.5 T scanner
(Signa HDx, General Electric, Milwaukee, WI) with gad-
olinium contrast enhancement. The mid sagittal T1 image
centered at the pituitary stalk was used to measure the
central height, maximum length, and cross-sectional area
of the gland. All measurements were obtained indepen-
dently by two experienced physicians (A.P., A.L.) blinded
to the clinical diagnosis with the aid of Codonics Software
v4.0.1 [12]. Pituitary adenomas were distinguished by
craniocaudal diameter taken in coronal sections into MA
(smaller than 10 mm) and macroadenoma (larger than
10 mm). Patients with pituitary diameter B2 mm and more
than 50 % filled with cerebrospinal fluid (CSF) were con-
sidered as total ES; patients with pituitary diameter C3 mm
but B7 mm (the mean diameter of normal pituitary gland
in adults) and less than 50 % filled with CSF were con-
sidered as partial ES [13].
Echocardiography
Participants underwent high-resolution M–B mode trans-
thoracic echocardiography using a 2.5 MHz Probe (Esaote
MyLab40, Esaote Europe B.V., The Netherlands). Two-
dimensional echocardiography and standard M-mode
measurements of left ventricle were performed as descri-
bed [14, 15]. EF%, LVMI, SLVD, DLVD, and EFT were
measured.
Dual-emission X-ray absorptiometry (DXA)
DXA measurement of body composition was performed
using a DXA scan (QDR 4500 W, Hologic Inc., Bedford,
MA, USA): lean mass, fat mass and bone mass were
obtained as percent and as amount of fat (in grams) with a
coefficient of variation\1 % for bone density and\1.5 %
for fat mass [16]. Delimiters for regional analysis were
determined by standard software (Hologic Inc., S/N 47168
VER. 11.2).
Statistical analysis
Data were analyzed by means of STATISTICA software,
version 8.0 (Stat Soft, Inc., Tulsa, Oklahoma) and MedCalc
Statistical Software version 13.0.2 (MedCalc Software
bvba, Ostend, Belgium). Results are expressed as
mean ± standard deviation (SD) unless otherwise speci-
fied. Differences between groups were analyzed using
ANOVA for continuous variables. Linear correlation and
multiple linear regression analyses were performed to
identify associations between GH AUC and metabolic
parameters and to identify the best predictor of GH peak
and HOMA-IR. The cut-off threshold for peak GH after
GHRH plus arginine was analyzed by receiver operating
curve (ROC). For the purpose of ROC analysis, we
assumed the patients with ES to be GHD according to our
results and other studies [17]. All statistical assessments
were considered significant if p \ 0.05.
Results
The demographic, anthropometric, and clinical character-
istics of the 184 patients with at least one symptom and one
objective sign possibly related to GHD disease [8, 9]
stratified according to the GH peak values after GHRH plus
arginine are shown in Table 1. Seventy patients had a peak
GH response to GHRH plus arginine lower than 4.2 lg/L
(mean ± SD, 2.31 ± 1.25 lg/L) that was compatible with
the diagnosis of GHD; all of them showed a complete or
partial ES except for one patient who had normal pituitary
(NP) according to morphological criteria. 16 out of 69
GHD ES patients (23.18 %) had multiple deficiencies: 15
out of 22 males had central hypogonadism, and two
showed also ACTH deficiency; one female had ACTH
deficiency. One hundred and fourteen patients [62 ES, 37
NP, ten microadenomas (MA) and five with other pituitary
abnormalities (OPA)] had a normal response to GHRH plus
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arginine (14.45 ± 12.64 lg/L, range 4.40–78.5) with
high variability. The group of patients with GHD was
heavier, with higher WC, SBP, TG, blood glucose, insulin,
HOMA-IR, WBC, and HbA1c values compared with nor-
mal GHRH plus arginine responders. Waist-to-hip ratio
(WHR), basal GH, and IGF-1 were significantly lower in
Table 1 Demographic,
anthropometric, and clinical
characteristics of the patients
according to peak GH values
after GHRH plus arginine test
Values represent mean ± SD
unless otherwise indicated
ES empty sella, MA
microadenoma, OPA other
pituitary abnormalities, NP
normal pituitary, BMI body
mass index, WC waist
circumference, WHR waist to
hip ratio, SBP systolic blood
pressure, DBP diastolic blood
pressure, HR heart rate, TG
triglycerides, Total-C total
cholesterol, HDL-C high density
lipoprotein cholesterol, HOMA-
IR homeostasis model
assessment of insulin resistance,
HbA1c glycated hemoglobin,
ESR erythrocyte sedimentation
rate, hs-CRP high-sensitivity
C-reactive protein, WBC white
blood cells, TSH thyroid
stimulating hormone, ACTH
adrenocorticotropic hormone,
PRL prolactin, GH growth
hormone, IGF-1 insulin-like
growth factor-1, IGF-1 SDS
IGF-1 standard deviation score,
EF ejection fraction, LVMI left
ventricular mass index, SLVD
systolic left ventricular
diameter, DLVD diastolic left
ventricular diameter, EFT
epicardial fat thickness, BMD
bone mineral density, UFDI
upper body fat deposition index,
MetS metabolic syndrome
a Peak GH value \4.2 lg/L
b Number of patients with
MetS, percentage value in
parentheses
Normal GHDa p value
n 114 70
ES 62 (54 %) 69 (98.6 %) \0.001
NP 37 (32 %) 1 (1.4 %) \0.001
MA 10 (8 %) 0 \0.05
OPA 5 (4 %) 0 ns
Gender (female/male) 99/15 48/22 \0.005
Age (years) 45.33 ± 13.16 47.94 ± 9.96 ns
Height (m) 1.63 ± 0.08 1.65 ± 0.11 ns
Weight (Kg) 100.92 ± 21.64 116.80 ± 31.65 \0.001
BMI (Kg/m2) 38.02 ± 7.11 42.70 ± 10.16 \0.001
WC (cm) 118.43 ± 16.43 128.90 ± 18.81 \0.001
WHR 0.98 ± 0.09 0.95 ± 0.07 \0.01
HR (beats/min) 69.31 ± 9.86 72.11 ± 9.64 ns
SBP (mmHg) 127.62 ± 16.41 133.05 ± 15.21 \0.05
DBP (mmHg) 80.21 ± 9.98 82.37 ± 9.69 ns
Total-C (mmol/L) 5.15 ± 0.92 5.3 ± 1.07 ns
LDL-C (mmol/L) 3.189 ± 0.86 3.2 ± 0.98 ns
HDL-C (mmol/L) 1.26 ± 0.32 1.2 ± 0.32 ns
TG (mmol/L) 1.52 ± 0.95 1.96 ± 1.31 \0.05
Glucose (mmol/L) 5.31 ± 0.89 5.85 ± 0.98 \0.001
Insulin (pmol/L) 157.17 ± 116.05 207.52 ± 147.10 \0.05
HOMA-IR 5.43 ± 4.20 8.18 ± 6.33 \0.001
HbA1c (%) 5.75 ± 1.05 6.27 ± 1.04 \0.01
HbA1c (mmol/mol) 39 ± 3.15 45 ± 3.12 \0.01
TSH (mIU/L) 1.57 ± 1.28 1.98 ± 1.52 ns
ACTH (pmol/L) 6.28 ± 3.95 7.03 ± 4.24 ns
PRL (pmol/L) 510.43 ± 325.65 488.26 ± 326.95 ns
GH (lg/L) 0.47 ± 0.79 0.22 ± 0.27 \0.01
IGF-1 (nmol/L) 21.38 ± 11.38 17.41 ± 7.00 \0.01
IGF-1 SDS -1.12 ± 2.06 -1.66 ± 1.76 ns
GH peak (lg/L) 14.45 ± 12.64 2.31 ± 1.25 \0.001
GH AUC (lg/L/h) 435.12 ± 329.92 84.98 ± 49.70 \0.001
EF (%) 66.51 ± 3.41 65.19 ± 4.23 \0.05
LVMI (g/m2) 108.97 ± 22.73 117.85 ± 19.74 \0.01
SLVD (mm) 30.48 ± 3.37 32.45 ± 3.93 \0.001
DLVD (mm) 49.53 ± 3.92 51.68 ± 4.23 \0.001
EFT (mm) 8.08 ± 1.12 8.49 ± 0.99 \0.05
L2-L4 BMD (g/cm2) 1.05 ± 0.12 1.01 ± 0.12 \0.05
Hip BMD (g/cm2) 1.01 ± 0.15 1.03 ± 0.15 ns
Body fat (%) 40.62 ± 6.11 42.52 ± 5.12 \0.05
Body lean (%) 59.38 ± 6.11 57.48 ± 5.12 \0.05
Arms fat (%) 49.15 ± 8.93 47.17 ± 12.40 ns
Legs fat (%) 42.55 ± 7.64 39.80 ± 9.55 \0.05
UFDI 1.89 ± 0.56 2.07 ± 0.54 \0.05
MetSb 56 (49 %) 46 (66 %) \0.05
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this group. The echocardiographic parameters related to the
left ventricle were significantly altered in the GHD group,
and lower EF% and higher EFT were present. Body com-
position by DXA revealed that in GHD patients, L2–L4
BMD and legs fat % were significantly lower, while the
UFDI value was significantly higher compared with normal
GHRH responders. Thus, the patients with GHD were
heavier but not fatter and showed a particular distribution
pattern of the adipose tissue characterized by a greater
UFDI. The prevalence of metabolic syndrome (MetS) in
the patients with GHD was higher compared with the
control group (66.0 vs. 49 %, p \ 0.037).
Linear correlation analyses to assess the relationships
between AUC of GH response to GHRH plus arginine test
and MetS diagnostic parameters, insulin and HOMA-IR
showed a significant inverse association between preserved
GH secretory capacity and all the parameters evaluated
with the only exception of HDL-C that showed a signifi-
cant direct relationship (Table 2).
Age- and sex-adjusted multiple regression analyses for
the association between GH peak response to GHRH plus
arginine test and selected covariates related to body com-
position and to pituitary morphology possibly involved in
the modulation of GH secretion (BMI, WC, UFDI, ES)
revealed that ES and UFDI were independent predictors of
GH secretory capacity (Table 3A). Age- and sex-adjusted
multiple regression analysis for the association of HOMA-
IR with BMI, WC, and GH peak values is presented in
Table 3B: GH peak was significantly associated with
HOMA-IR. Furthermore, the odds ratio for GHD in ES
patients was 63.44 (95 % CI 8.53–471.85; p = 0.0001).
ROC analysis (Fig. 2) to identify the GH cut-off value
after GHRH plus arginine revealed that the cut-off with
best pair of values for sensitivity and specificity (80.34 and
91.30 % respectively) was 5.73 lg/L.
Discussion
Adult GHD causes a clinical syndrome characterized by
increased fat mass, adverse changes in lipid metabolism,
carbohydrate metabolism, and cardiovascular function [18–
20]. GH replacement therapy normalizes many of these
signs and symptoms, but it is not approved in the absence
of an appropriate clinical context, namely structural HP
defects [21, 22]. The estimated incidence of adult-onset
GHD is between 12 and 19 cases per million of the pop-
ulation [23]. However, the true incidence of adult-onset
GHD remains unknown, owing in part to the lack of
standardization of diagnostic criteria, and in part because
not all patients at risk are routinely assessed for the diag-
nosis of GHD. Consensus statements indicate only adult
patients with structural HP disease, surgery or irradiation in
these areas, head trauma, or evidence of other pituitary
hormone deficiencies are worth to be considered for eval-
uation for adult-acquired GHD [8, 9]. Moreover, screening
in a clinical setting for GHD in obese patients is generally
Table 2 Linear correlation analyses comparing AUC of GH response
to GHRH plus arginine test and diagnostic parameters of MetS
Mean ± SD Pearson R p
AUC (lg/L/h) 301.34 ± 312.61
WC (cm) 122.42 ± 18.05 -0.39 0.000
SBP (mmHg) 129.62 ± 16.15 -0.19 0.012
DBP (mmHg) 81.00 ± 9.90 -0.18 0.020
HDL-C (mmol/L) 1.13 ± 0.19 0.19 0.020
Triglycerides (mmol/L) 1.66 ± 1.00 -0.24 0.001
Glucose (mmol/L) 5.51 ± 0.96 -0.32 0.000
Insulin (pmol/L) 176.13 ± 130.50 -0.22 0.005
HOMA-IR 6.46 ± 5.25 -0.27 0.000
AUC area under the curve, WC waist circumference, SBP systolic
blood pressure, DBP diastolic blood pressure, HDL-C high density
lipoprotein cholesterol, HOMA-IR homeostasis model assessment of
insulin resistance
Table 3 Multiple linear
regression analysis for the
association between GH peak
(A) and HOMA-IR (B) and
selected covariates adjusted for
sex and age
(A) R = 0.58162782,
R2 = 0.33829092 adjusted
R2 = 0.30376697
(B) R = 0.45273682,
R2 = 0.20497063 adjusted
R2 = 0.18069492
Covariates b SE T (138) B SE p value
(A) Dependent variable, GH peak
Intercept 36.81915 10.30003 3.57467 0.000517
BMI (kg/m2) -0.083590 0.133891 -0.15673 0.25105 -0.62431 0.533682
WC (cm) -0.111171 0.133418 -0.08991 0.10790 -0.83326 0.406456
UFDI -0.194511 0.085731 -3.70997 1.63517 -2.26886 0.025175
ES 0.437956 0.082668 11.97970 2.26126 5.29780 0.000001
(B) Dependent variable, HOMA-IR
Intercept 0.78472 3.042892 3.877664 0.434033
BMI (kg/m2) 0.230181 0.144283 1.59534 0.148831 0.093291 0.113046
WC (cm) 0.062239 0.147945 0.42069 0.018510 0.043999 0.674670
GH peak (lg/L) -0.219659 0.083342 -2.63563 -0.101282 0.038428 0.009412
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not accepted, mainly because of the negative influence of
abdominal and visceral obesity on the secretion of GH [24].
However, a number of clinical questions still remain
unanswered. Is the blunted GH response always functional
(namely, correctable with weight reduction) or, in a pro-
portion of obese patients, might GHD be organic? What is
the clinical context for the evaluation of GHD in obese
individuals? How much does GHD contribute to the car-
diometabolic risk factors associated with obesity? Are
there potential therapeutic consequences in terms of GH
replacement therapies?
We found that among obese individuals with nonspecific
signs and symptoms of GHD, ES is frequent, and the
majority of them have a biochemically severe GHD, with a
strong association between GHD and ES. Moreover,
23.18 % of ES GHD patients show multiple hormonal
deficiencies. These data suggest ES as an associated
organic cause in a proportion of formerly defined ‘‘idio-
pathic’’ GHD and open a new scenario on the actual
prevalence of organic GHD in obesity. ES is seen in a
range between 8 and 35 % of the general population [25].
Incidence and prevalence of hypopituitarism are estimated
to be 4.2 per 100,000/years and 45.5 per 100,000, respec-
tively [26]; this means a prevalence of less than 0.05 %.
These data are inconsistent with the reduced GH response
to GHRH plus arginine found in 39.2–61 % of the patients
with primary ES [5, 27], which would predict a much
higher prevalence of GHD. Thus, in obesity, ES is under
diagnosed, and the expected prevalence of GHD could be
underestimated. These findings indicate that complicated
obesity may underlie GHD, and the clinical context to
search for GHD in obese could be broader than was sup-
posed. A rational consequence, worth being considered
further, is that the quite variable improvement of GH
secretion after weight loss might not occur when GHD and
ES associate. Accordingly, persistence of ES despite a
significant weight loss after bariatric surgery has been
reported [28], suggesting that in the presence of an organic
basis for GHD, weight reduction, although beneficial,
could not be curative.
Low endogenous GH secretion in the obese state asso-
ciates with increased cardiometabolic risk factors [21].
Reduced GH secretion has been correlated with an adverse
lipid and lipoprotein profile, increased abdominal adipose
tissue mass, higher hs-CRP, and increased prevalence of
diabetes [18]. However, since GH levels decline with aging
and weight gain, and both elderly and obese individuals
have a higher risk of developing cardiometabolic diseases
independent of reduced GH [29], it is difficult to determine
whether changes in metabolic environment are specifically
related to GHD or other concomitant conditions. In line
with previous reports [18], we found an inverse association
between GH secretory capacity and the essential compo-
nents of MetS, HbA-1c, and HOMA-IR values. Our find-
ings extend the data available so far in the sense that the
main parameter associated with insulin resistance is the GH
peak independently from BMI and WC.
In our obese GHD patients, we found reduced lumbar
BMD and lean body mass percentage and increased UFDI,
a DXA-derived parameter strictly related to EFT that
conveys information about the ratio between subcutaneous
and visceral fat [17, 30]. All these conditions are known
signs of GHD, virtually ascribable to the reduced action of
GH on muscle, bone, and fat [21, 31] and offer a possible
explanation for the coexistence of sarcopenia and osteo-
penia in a subset of obese patients [32].
LVMI, SLVD, DLVD, and EFT were significantly
increased in our GHD group, suggesting cardiac structural
Optimal criterion = 5.73 µg/L
Sensitivity 80.34% (72.0-87.1)
Specificity 91.30% (79.2-97.6)
AUC 0.912 (95% CI 0.858-0.951) 
P<0.0001
G
H
 p
ea
k,
µg
/L
 
No ES ES
5.73 µ
µ
g/L 
4.2 g/L 
A B
Fig. 2 Sensitivity and specificity of peak serum GH response to the
GHRH plus arginine test in the study population. In panel A, ROC
analysis that includes all the patients tested revealed an AUC of 0.912
(95 % CI 0.858–0.951); optimal criterion, sensitivity, and specificity
with confidence intervals are shown in the box. In panel B, the use of
a cut-off value of 5.73 lg/L of GH to minimize the total classification
error of GHD had a sensitivity and specificity of 80.34 and 91.30 %,
respectively, for ES. The currently accepted cut-off value of 4.2 lg/L
is also shown
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changes related to the impaired GH secretion capacity,
possibly due to the increased intramyocellular fat deposi-
tion seen in individuals with blunted GH response [33, 34].
Some studies have disclosed beneficial effects of recom-
binant human GH treatment in patients with idiopathic
dilated cardiomyopathy and ischemic cardiomyopathy [35,
36]; exogenous GH is able to improve significantly cardiac
function, with decreases in left ventricular end-diastolic
and end-systolic dimensions [37]. Furthermore, EFT was
significantly reduced after short-term GH replacement in
patients with adult-onset GHD [38]. Our results do not
confirm the decrease of cardiac mass seen in other studies
involving GHD patients [39, 40], although these data were
taken from small populations of normal/overweight
patients. The cardiac abnormalities we found might be a
typical trait of organic GHD in obesity. Overall, these
findings suggest that the GH secretory capacity is a major
determinant of cardiac morphology and metabolic pheno-
type of the obese patients.
Multiple regression analysis, performed to evaluate the
influence of different covariates on GH secretion, shows
that pituitary morphology and to lesser extent UFDI, but
not BMI and WC, are related to GH peak values. These
new findings suggest that the presence of ES might be the
strongest determinant of reduced GH secretion in obese
patients. Although novel, this is not unexpected since brain
structural defects [9], including ES syndrome and all the
conditions compatible with acquired ES (traumatic brain
injury, surgery, irradiation, infarction, inflammatory or
infiltrative disorders), are recognized causes of organic GH
deficiency. Interestingly, the GH peak response to GHRH
plus arginine stimulus, more than BMI and WC, associates
with HOMA-IR, suggesting that the GH secretory capacity
is the major independent predictor of insulin resistance in
the obese patients with symptoms and signs of GHD.
Obesity is the most important confounding factor for the
diagnosis of nonfunctional GHD in adults. Nearly half of
the patients with acquired HP disease are overweight or
obese and normal GH secretory capacity is crucial for
cardiometabolic health; thus, a proper GH peak cut-off
value is important to identify organic GHD in obese
patients. We suggest a cut-off value of 5.73 lg/L GH peak
response to GHRH plus arginine for GHD that derives from
a ROC analysis based on ES as positive condition for
organic GHD [5, 17]. This cut-off differs from the cur-
rently accepted 4.2 lg/L GH diagnostic cut-off peak value
in obese subjects. Based on the old and new cut-off,
respectively 70 (38 %) and 98 (53 %) of the 184 patients
with at least one symptom and one objective sign related to
GHD were classified as having severe GHD. We think our
cut-off value as appropriate, with ES being the covariate
most strongly associated with the GH peak, in comparison
with WC, BMI, IGF-1, impairment of lipid profile, reduced
bone mineral density, and cardiac abnormalities. Further-
more, our cut-off is similar to the 5.5 lg/L value proposed
in obese patients aged 26–65 years [41], confirming that
testing for GHD should be performed in patients with
underlying HP disorders and strengthening the concept that
ES should not be considered as merely an incidental find-
ing, rather as a structural condition likely associated with
GHD in obesity.
Clinical trials assessing the effects of GH treatment in
obese patients showed consistent reductions in adipose
tissue mass and in particular visceral depots [18]. More-
over, studies in patients with abdominal obesity demon-
strate a marked effect of GH therapy on lipid and glucose
homeostasis [18]. Therefore, administration of recombinant
human GH has great potential to influence the onset and
metabolic consequences of obesity, but the clinical use in
obesity remains controversial [18, 21]—although, a recent
study conducted on a large population of adult onset GHD
patients, demonstrates that, in GH-treated patients, mor-
tality decreases in total and due to malignancy compared
with untreated patients, even after adjustment for all pos-
sible measured confounders [42].
Conclusions
The coexistence of morphological alterations and signs/
symptoms of HP disease is frequent in obese patients. Our
data, providing ES as an underlying organic cause for GHD
in a portion of obese patients, portend new therapeutic
outcomes. Whether GH replacement may improve obesity
and the associated cardiometabolic risk factors in obese
individuals with GHD and ES needs further studies.
Although the question remains whether ES and GHD are
common co-travelers due to obesity and their cooccurrence
reflects a causal effect of fat mass on ES pathogenesis and
GHD, the high concurrence of ES and severe GHD in
obese patients may have important consequences both for
clinical screening and therapeutic approach, since the
recovery of normal GH secretion because of GHD arising
from ES is uncertain and the GH replacement in these
patients might be appropriate.
There are some limitations in our study. This was a
cross-sectional study, so we could not assess the causal
relationship between the covariates evaluated and GHD.
Second, the sex structures of the cohort is not balanced, but
the interference of this factor with the results is unlikely
since all the analytic data were corrected for age and sex.
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